Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DCTH 
Delcath Systems Inc (DCTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: DCTH (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $24.33
1 Year Target Price $24.33
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 117.72% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 385.49M USD | Price to earnings Ratio 122.44 | 1Y Target Price 24.33 |
Price to earnings Ratio 122.44 | 1Y Target Price 24.33 | ||
Volume (30-day avg) 6 | Beta 0.82 | 52 Weeks Range 8.08 - 18.23 | Updated Date 08/30/2025 |
52 Weeks Range 8.08 - 18.23 | Updated Date 08/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate 0.03 | Actual 0.07 |
Profitability
Profit Margin 3.18% | Operating Margin (TTM) 10.72% |
Management Effectiveness
Return on Assets (TTM) 4.16% | Return on Equity (TTM) 3.57% |
Valuation
Trailing PE 122.44 | Forward PE 156.25 | Enterprise Value 305481408 | Price to Sales(TTM) 5.49 |
Enterprise Value 305481408 | Price to Sales(TTM) 5.49 | ||
Enterprise Value to Revenue 4.35 | Enterprise Value to EBITDA 57.93 | Shares Outstanding 34981300 | Shares Floating 34028713 |
Shares Outstanding 34981300 | Shares Floating 34028713 | ||
Percent Insiders 2.72 | Percent Institutions 52.75 |
Upturn AI SWOT
Delcath Systems Inc
Company Overview
History and Background
Delcath Systems Inc. was founded in 1988. It is a specialty pharmaceutical company focused on oncology, specifically hepatic directed therapy.
Core Business Areas
- Chemosaturation Therapy: Chemosaturation is Delcath's primary business segment, involving the use of percutaneous hepatic perfusion (PHP) to deliver high doses of chemotherapy directly to the liver while minimizing systemic exposure.
Leadership and Structure
Delcath Systems Inc.'s leadership team includes Gerard Michel (Chief Executive Officer), Joe Markey (Chief Financial Officer), and Dr. Vojislav Vukovic (Chief Medical Officer). The company has a board of directors that oversees its operations.
Top Products and Market Share
Key Offerings
- Melphalan/HDS: Melphalan/HDS (Hepatic Delivery System) is Delcath's primary product used in Chemosaturation Therapy. Market share data specific to Melphalan/HDS is not publicly available, but Delcath faces competition from other systemic chemotherapy treatments and liver-directed therapies. Competitors in liver-directed therapies include companies providing radioembolization, transarterial chemoembolization (TACE) and ablation technologies.
Market Dynamics
Industry Overview
The oncology market is large and growing, with increasing demand for targeted therapies and improved treatment options for liver cancers. The industry is characterized by innovation, regulatory scrutiny, and pricing pressures.
Positioning
Delcath is positioned as a provider of liver-directed chemotherapy through its Chemosaturation System. Its competitive advantage lies in its ability to deliver high doses of chemotherapy directly to the liver while minimizing systemic toxicity. This is a differentiator from other systemic chemotherapy approaches.
Total Addressable Market (TAM)
The TAM for liver-directed therapies is estimated in the billions of dollars annually. Delcath's positioning within this TAM is focused on patients with unresectable hepatic metastases from cancers such as melanoma, representing a significant, but still niche segment of the larger liver cancer treatment market.
Upturn SWOT Analysis
Strengths
- Proprietary Chemosaturation Technology
- Targeted delivery of chemotherapy
- Reduced systemic toxicity compared to traditional chemotherapy
- Approved treatment option for certain liver cancers
Weaknesses
- Limited market adoption
- High cost of treatment
- Requirement for specialized medical centers
- Dependence on a single product
Opportunities
- Expansion into new indications
- Partnerships with larger pharmaceutical companies
- Increased awareness and adoption of Chemosaturation Therapy
- Geographic expansion
Threats
- Competition from other liver-directed therapies
- Regulatory challenges
- Reimbursement issues
- Development of new systemic therapies
Competitors and Market Share
Key Competitors
- MRK
- BAYRY
- EISAI
Competitive Landscape
Delcath's advantage is the targeted nature of its therapy; disadvantages are the cost and limited availability compared to systemic options.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent, dependent on regulatory approvals and market adoption of Chemosaturation Therapy.
Future Projections: Analyst estimates suggest potential for growth with expansion into new indications and increased market penetration.
Recent Initiatives: Recent strategic initiatives include pursuing new indications for Chemosaturation Therapy and expanding market access.
Summary
Delcath Systems Inc. is a niche player in the oncology market with a unique liver-directed therapy. The company's financial stability is dependent on successful market adoption and expansion. It faces competition from established pharmaceutical companies. Expansion into new treatment areas and geographies are critical for success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Company website
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Delcath Systems Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2018-05-29 | CEO & Director Mr. Gerard J. Michel MBA, MS | ||
Sector Healthcare | Industry Medical Devices | Full time employees 96 | Website https://www.delcath.com |
Full time employees 96 | Website https://www.delcath.com | ||
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.